Få tillgång till
till ratingen av Finrange-aktier
till ratingen av Finrange-aktier
Med denna tariff kommer du att kunna använda tjänsten utan begränsningar, all information kommer att vara tillgänglig
Betyg Finrange
Uppkommande händelser Orgenesis Inc
Alla evenemang
Inga kommande evenemang planerade
Sammanfattande analys Orgenesis Inc
Få tillgång till
till ratingen av Finrange-aktier
till ratingen av Finrange-aktier
Med denna tariff kommer du att kunna använda tjänsten utan begränsningar, all information kommer att vara tillgänglig
Intäkter och nettointäkter Orgenesis Inc
Alla parametrar
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
Adress:
20271 Goldenrod Lane, Germantown, MD, United States, 20876
